profit from every $100 of sales.
$0$100
Beam Therapeutics
$24.03-6.90% today
+9.9% in 1 year
1-year low $20.601-year high $37.92
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Beam Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $60.9 million in 2022 to $140 million in 2025, with -$80.0 million of profit last year.
SalesProfit
Beam Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Beam Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 34.8× · Expensive | ||
 Regeneron Pharmaceuticals | 21.8× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.3× · Fair price |
AI analysis
An AI analyst reads Beam Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 61 | 378 | 64 | 140 | |
| – | – | – | – | |
| -338 | -176 | -416 | -384 | |
| -316 | -156 | -394 | -361 | |
| -289 | -133 | -377 | -80 | |
| -4.13 | -1.72 | -4.58 | -0.81 | |
| – | – | – | – | |
| -555.6% | -46.7% | -654.3% | -274.6% | |
| -474.5% | -35.1% | -593.1% | -57.2% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 1,342 | 1,460 | 1,104 | 1,481 |
| Cash | 233 | 436 | 282 | 295 |
| Total debt | 179 | 173 | 161 | 154 |
| Total liabilities | 608 | 478 | 370 | 243 |
| 733 | 981 | 734 | 1,238 | |
| 70 | 77 | 82 | 99 | |
| -29.3% | -12.1% | -36.7% | -21.8% | |
| -39.4% | -13.5% | -51.4% | -6.5% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 23 | -149 | -347 | -345 | |
| 49 | 34 | 9 | 15 | |
| -26 | -183 | -356 | -360 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 84 | 99 | 121 | 94 |
Valuation
- –
- –
- –
- 2.1×
- 17.8×
- –
- –
- -14.5%
- -3.2%
- 0.0%
Profitability
- -32.4%
- -274.6%
- -57.2%
- -38.3%
- -22.3%
- -25.6%
- -5.9%
- -4.4%
- -26.4%
- 253.2%
Growth
- +31.9%
- –
- −1.1%
- –
- +12.2%
Financial health
- -0.4×
- 0.12
- 16.9%
- -34.9×
- 13.09
- 16.99
- 0.11
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 19%of 952
Top 18%of 870
Bottom 7%of 985
What analysts expect
- Average price target
- $40.83
- Range
- $26.00 – $74.00
- 2 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | -0.91 | -0.87 | −4.6% |
| Feb 24, 2026 | -0.10 | -1.13 | +91.2% |
| Nov 4, 2025 | -1.10 | -0.98 | −12.2% |
| Aug 5, 2025 | -1.00 | -1.04 | +3.8% |
| May 6, 2025 | -1.24 | -1.11 | −11.7% |
| Feb 25, 2025 | -1.09 | -1.25 | +12.8% |
| Nov 5, 2024 | -1.17 | -1.13 | −3.5% |
| Aug 6, 2024 | -1.11 | -1.13 | +1.8% |
News
Cathie Wood Keeps Buying Beam Therapeutics on the Dip. Should You Follow Her Lead?Yahoo Finance · Oct 18, 2026Beam drops after updating Phase 1/2 trial data for gene-editing drugSeeking Alpha · Sep 8, 2026Beam Global outlines nearly $3M in rent savings over 5-year Yuma lease as Q2 revenue rises 174% q/qSeeking Alpha · Aug 20, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
28No pass
Benjamin Graham
51No pass
Philip Fisher
34No pass
Peter Lynch
70Pass
Joel Greenblatt
0No pass
Charlie Munger
25No pass
Terry Smith
31No pass
Questions about Beam Therapeutics
Is Beam Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Beam Therapeutics AI analysis
What does Beam Therapeutics do?
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It is in Biotechnology, based in Cambridge, MA, United States, with 522 employees.
Does Beam Therapeutics pay a dividend?
No. Beam Therapeutics does not pay a dividend at the moment.
Is Beam Therapeutics stock halal?
Questionable. Beam Therapeutics sits in a grey zone: short-term investments may earn interest; type not reported. How we check
How has Beam Therapeutics stock done over the past year?
Up 9.9% over the past twelve months, to $24.03. It traded between $20.60 and $37.92 and is 36.6% below its high.
Who are Beam Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Beam Therapeutics's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.